-
Wind River Partners, LLC
Distance: 2.1 Mi2214 Windsor Cir
19008-2206 Broomall -
Caliber Associates
Distance: 5.2 Mi125 Strafford Ave Ste 112
19087 Wayne -
SparRx
Distance: 5.2 Mi175 Strafford Ave Ste One 503
19087-3396 Wayne -
Training & Communications Group, Inc
Distance: 5.5 Mi1137 Lancaster Ave.
19312 Berwyn -
JPC Partners LLC
Distance: 5.5 Mi316 Maple Ave
19081-1411 Swarthmore
Website Links
Description
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland.
Formed in 2010, AltheRx Pharmaceuticals is a privately held development company whose business model is to advance projects through clinical development and create partnerships with biopharmaceutical companies for commercialization. The Company’s first product, Solabegron, is a highly selective and potent beta3-adrenoceptor agonist in development for the reduction of symptoms of Overactive Bladder and Irritable Bowel Syndrome.
Incyte Corporation is a biopharmaceutical company focused on discovering and developing proprietary, orally available drugs for serous unmet medical needs in oncology and inflammation. Incyte has a portfolio of novel compounds that have advanced into late-stage clinical development.
Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. We are developing our lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease.